At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLYS Mineralys Therapeutics, Inc.
Trading 06-08 15:52:46 EDT
22.58
-1.11
-4.70%
High23.80Low22.30Vol1.67M
Open23.76D1 Closing23.69Amplitude6.33%
Mkt Cap1.99BTradable Cap1.49BTotal Shares88.16M
T/O38.07MT/O Rate2.53%Tradable Shares66.03M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)
TIPRANKS  ·  06-04
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)
Mineralys Therapeutics falls -12.7%
TIPRANKS  ·  06-03
Mineralys Therapeutics falls -12.7%
Mineralys prices offering of 5.66M shares of common stock at $26.50
TIPRANKS  ·  06-03
Mineralys prices offering of 5.66M shares of common stock at $26.50
BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway
Reuters  ·  06-03
BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway
BUZZ-Mineralys Therapeutics falls after $150 mln stock deal
Reuters  ·  06-03
BUZZ-Mineralys Therapeutics falls after $150 mln stock deal
BRIEF-Mineralys Therapeutics Announces Pricing Of $150 Million Underwritten Offering Of Common Stock
Reuters  ·  06-03
BRIEF-Mineralys Therapeutics Announces Pricing Of $150 Million Underwritten Offering Of Common Stock
Mineralys to repurchase future royalty payments in Tanabe license agreement
TIPRANKS  ·  06-03
Mineralys to repurchase future royalty payments in Tanabe license agreement
Mineralys Therapeutics prices 5,660,378-share offering at $26.5 per share
Reuters  ·  06-03
Mineralys Therapeutics prices 5,660,378-share offering at $26.5 per share
Mineralys inks up to $500 million senior secured term loan with Pharmakon Advisors
Reuters  ·  06-03
Mineralys inks up to $500 million senior secured term loan with Pharmakon Advisors
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
THOMSON REUTERS  ·  06-03
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
Mineralys Therapeutics - Secures $500 Mln Senior Secured Term Loan Facility From Pharmakon Advisors
THOMSON REUTERS  ·  06-03
Mineralys Therapeutics - Secures $500 Mln Senior Secured Term Loan Facility From Pharmakon Advisors
Mineralys Therapeutics - Prices $150 Mln Common Stock Offering
THOMSON REUTERS  ·  06-03
Mineralys Therapeutics - Prices $150 Mln Common Stock Offering
Mineralys Therapeutics - to Repurchase Lorundrostat Royalty Obligation for $200 Mln Upfront, up to $100 Mln in Milestones
THOMSON REUTERS  ·  06-03
Mineralys Therapeutics - to Repurchase Lorundrostat Royalty Obligation for $200 Mln Upfront, up to $100 Mln in Milestones
Buy Rating Reiterated on MLYS as Launch-HTN Data Highlight Lorundrostat’s Efficacy in Resistant CKD Hypertension; $54 Price Target Unchanged
TIPRANKS  ·  06-02
Buy Rating Reiterated on MLYS as Launch-HTN Data Highlight Lorundrostat’s Efficacy in Resistant CKD Hypertension; $54 Price Target Unchanged
Mineralys publishes ESH 2026 presentation on lorundrostat in CKD hypertension trial
Reuters  ·  06-01
Mineralys publishes ESH 2026 presentation on lorundrostat in CKD hypertension trial
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  06-01
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mineralys Therapeutics presents new data for lorundrostat
TIPRANKS  ·  06-01
Mineralys Therapeutics presents new data for lorundrostat
BRIEF-Mineralys Therapeutics Presents New Data From The Phase 3 Launch-Htn Trial Of Lorundrostat
Reuters  ·  05-30
BRIEF-Mineralys Therapeutics Presents New Data From The Phase 3 Launch-Htn Trial Of Lorundrostat
Mineralys Therapeutics Presents New Data From the Phase 3 Launch-Htn Trial of Lorundrostat in Participants With Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
THOMSON REUTERS  ·  05-30
Mineralys Therapeutics Presents New Data From the Phase 3 Launch-Htn Trial of Lorundrostat in Participants With Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Mineralys Therapeutics: Lorundrostat Showed Significant Blood Pressure Reductions in Ckd Patients in Phase 3 Launch-Htn Trial
THOMSON REUTERS  ·  05-30
Mineralys Therapeutics: Lorundrostat Showed Significant Blood Pressure Reductions in Ckd Patients in Phase 3 Launch-Htn Trial

Introduction

Company Name.
Mineralys Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Issue price:
--